India's Cadila gets regulatory nod to repurpose Hepatitis C drug for COVID-19

BENGALURU, April 23 (Reuters) - India's Cadila Healthcare Ltd CADI.NS received approval from local regulators to use a Hepatitis C drug as a treatment for COVID-19, the drugmaker said on Friday.

(Reporting by Sachin Ravikumar in Bengaluru)

((; +91 80 6182 2754; Twitter: @sachinr27))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.